Live Biotherapeutic Products and Microbiome Medicine

The gut microbiome is linked to obesity, autoimmune diseases, depression, and cancer treatment response. Live Biotherapeutic Products deliver specific microbial strains at therapeutic doses. The FDA approved Vowst for C. diff in 2023 as the first microbiome therapeutic. By 2030 the microbiome therapeutics pipeline is projected to exceed 200 active clinical trials targeting conditions from mental health to metabolic disease.